initi coverag bellu health toronto blu alpha seri descript
within report outperform rate price bellu focus
develop select antagonist patient refractory/idiopath chronic
cough affect adult popul lack effect therapi target
receptor diseas partial valid posit phase iib data affer
antagonist phase iib data led acquisit
affer merck up-front non-intend engag receptor
result major patient experienc taste-alter complet tast loss
enhanc select receptor phase result healthi volunt
show minim effect tast favor pk profil potenti
best-in-class antagonist phase ii trial chronic cough plan begin
base dilig project reach risk-adjust sale
non-risk adjust sale
patient refractory/idiopath chronic cough need improv therapi
cough reflex import defens mechan clear excess secret foreign materi
respiratori tract howev patient whose airway becom hypersensit
cough hour becom excess signific physic psychosoci
implic individu qol chronic cough commonli associ pulmonari
upper airway disord treat accordingli case option limit
come refractory/idiopath chronic cough novel therapi approv
year
outsid non-pharmacolog therapi like speech patholog physiotherapi physician
larg left prescrib neuromodul like gabapentin pregabalin slow-releas morphin
demonstr consist efficaci also come signific given
chronic cough affect popul patient diseas need novel
therapi safe effect
year left
short interest float
financi cad
affer put chronic cough industri radar affer antagonist
origin develop variou pain indic
demonstr strong efficaci refractory/idiopath chronic cough popul
random phase iib studi bid dose gefapix led reduct awak
cough frequenc baselin well statist signific decreas compar placebo
cough frequenc data also support signific improv patient-
report cough sever measur visual analog score
phase iib data result acquisit affer merck up-front
howev note toler profil gefapix somewhat problemat given
chronic natur diseas patient receiv bid dose report form
tast alter complet tast loss patient discontinu treatment
due taste-rel ae although mechan behind tast disturb entir
understood hypothes due drug non-intend engag
receptor commonli found tast bud on-going phase trial gefapix merck
test mg mg bid dose attempt thread needl effect
cough tast
analyst certif disclosur pleas see page
profil best-in-class antagonist sinc gefapix posit phase iib data readout bayer shionogi asset
current develop japan bellu health join merck develop antagonist refractory/idiopath
chronic cough knowledg bellu health optim asset bunch select
receptor comparison gefapix select bayer asset select assum hypothesi
main driver cough reflex hypersensit correct best chanc mitig cough frequenc minim
tast effect
theori held true thu far preclin clinic studi anim model exhibit compar anti-tuss efficaci
durat respons gefapix significantli lower effect tast addit healthi subject phase trial
report tast disturb project therapeut dose bid good see us indic target
engag manag believ mg bid dose suffici fulli block receptor given result
gefapix base what present thu far major kol spoke believ compar level
efficaci gefapix refractory/idiopath cough patient maintain superior toler profil howev given advantag tast
kol also indic would still favor gefapix even slightli less effect top expect
patient milder diseas larger efficacy/tast alter window sever diseas point
lower efficaci threshold achiev rel gefapix order obtain market share said phase data still need
achiev statist signific
upcom phase ii data bayer chronic cough asset provid insight vs debat major
literatur kol spoke point receptor close associ cough reflex hypersensit
howev debat role cough near-term readout provid insight topic upcom phase
ii data bayer select program bayer reveal much detail characterist
patent claim asset select receptor posit efficaci result on-going
studi would enforc main driver cough direct readthrough bellu program primari complet phase i/ii
trial bayer asset estim data could come earli bayer provid guidanc view
readout valu inflect point bellu given expect come phase ii data
bayer also conduct drug-drug interact ddi studi parallel phase i/ii clinic studi may signifi safeti issu
target relat potenti better antagonist increas specif bayer asset enough
complet overcom tast disturb associ target engag ddi studi result influenc patient select
product dose use either way kol note would want prescrib antagonist bayer bellu gefapix
compar efficaci accompani tast effect
cough expert believ antagonist promis treatment class develop multipl drug class
develop chronic cough antagonist advanc demonstr anti-tuss benefit clinic fact kol
spoke believ promis target develop diseas receptor antagonist trp modul
consid interest therapi refractory/idiopath chronic cough failur serlopit
well variou asset indic great target diseas nerr expect read
data phase iib studi receptor antagonist orvepit first half recent neuron nicotin acetylcholin
receptor voltage-g sodium channel antagon consid possibl form therapi chronic cough limit
mechanist proof concept approach time notabl howev dr michael kitt affer previou join attenua
ceo guid clinic develop nicotin receptor antagonist phase ii data expect end
potenti expand pain indic provid addit upsid receptor link atp modul
sensori neuron throughout bodi dysregul sensit neuron link multipl version pain
irrit condit like overact bladder irrit bowel syndrom chronic itch recent analysi also shown express much
higher women suffer endometriosis-rel pain merck gefapix recent enter phase ii clinic studi bayer
phase develop indic result bellu develop endometriosis-rel pain time
compani could expand develop presum continu perform best-in-class antagonist without safeti toler
concern model incorpor indic outsid chronic cough time could addit upsid estim
mid begin phase ii studi chronic cough
mid phase ii result chronic cough
bellu health toronto blu new flavor inhibitor
chronic cough outperform rate price target
alpha seri
lifesci capit alpha seri intend encompass high conviction/impact idea within healthcar sector
analys recommend base deep fundament analysi goal help creat alpha
investor long run
close march
refractory/idiopath chronic cough remain area unmet need larg address patient popul
cough reflex hypersensit recent character believ affect adult popul
novel anti-tuss therapi approv year physician especi us want
prescrib narcot treatment option result opioid epidem
antagonist drug class alreadi clinic valid chronic cough merck gefapix
phase iib trial gefapix bid demonstr statist signific reduct awak cough frequenc
patient-report cough sever compar placebo merck acquir affer
pharmaceut june up-front mileston base posit result
howev patient report form tast alter dysgeusia/hypogeusia/ageusia dose like due
concurr target engag receptor addit patient discontinu treatment
bid due taste-rel ae meaning problem given chronic natur diseas
bellu health optim antagonist expect similar efficaci gefapix
without associ tast effect
select receptor possibl make best-in-class asset compar
competitor gefapix select bayer asset phase ii trial select
preclin anim studi demonstr compar anti-tuss efficaci durat effect gefapix minim
tast effect subject treat experienc transient tast disturb phase studi
twelve-month price target base dcf valuat start slide assum wacc termin growth rate
million fulli dilut share pro-forma assumpt follow
chronic cough enter market chronic cough us start rest world given
assumpt third antagonist reach market best-in-class profil estim risk-adjust sale
po non-risk adjust sale analysi assum start net price
elig patient us chronic cough year time launch peak penetr us rest world
make grow fraction us sale note baselin assumpt potenti conserv exampl although
merck bellu are/wil enrol patient studi chronic cough year condit defin symptom
week possibl antagonist also use patient symptom year also estim preval
chronic cough adult popul assumpt use preval number given seem accur base
real-world observ lastli independ price consult estim could price price
treatment like depend price first-to-market antagonist assum net price model note
estim market uptak could chang substanti clinic data becom avail compet program
futur potenti indic outlin within report antagonist potenti indic outsid chronic cough
endometriosis-rel pain bayer merck test antagonist condit current includ possibl futur
sale indic model although could chang inform learn
partner program bellu health also econom interest partner program pulmonari sarcoidosi phelan
mcdermid syndrom amo pharma homozyg alzheim diseas alzheon includ potenti upsid program
model time note project complet fund partner
expens estim cog revenu time launch decreas model expens flat
rate start time launch account post-market studi etc estim market sg expens ramp
time launch repres sale patent expir base histor comparison
scenario analysi upsid base case downsid
success expand addit indic
receiv extens patent protect
antagonist delay obtain regulatori approv
sale surpass expect
approv chronic cough launch late
effect gefapix clinic studi
associ tast disturb
achiev risk adjust sale
fail achiev posit result futur clinic studi
obtain regulatori approv
chronic cough market develop expect result
less expect revenu
less effect compet antagonist
consid invest bellu high-risk invest reason limit follow risk
clinic bellu health valuat depend upon success outcom on-going clinic studi
sever major inflect point compani within next month data prior studi highlight
drug safeti pk profil number patient report limit may predict futur clinic
regulatori clinic develop regulatori risk surround asset develop despit
signific time financi invest compani guarante reach market
market despit belief potenti becom differenti therapi chronic cough treatment
paradigm space competit multipl product clinic develop sale may ultim meet project
price reimburs payer restrict level reimburs will cover significantli
impact potenti sale achiev addit price treatment may maintain time
particularli ex-u increas price pressur
financ bellu may need rais addit capit dilut financ may abl obtain
suffici capit fund plan develop program market launch
clinic allergist
embed practic
cough patient one
highest enrol chronic
cough trial variou
kol emphas fact refractory/idiopath chronic cough neuropath problem
frustrat major doctor treat rather consid cough
reflex hypersensit everi possibl diseas elimin believ
introduct new therapi help move convers forward
practic kol would prescrib antagonist chronic cough
patient note dire need novel drug gabapentin opiat
substanti patient like persist lifestyl changes/speech therapi
kol expect effect gefapix term efficaci
mechan cough complet understood believ bellu health preclin
phase data valid main receptor target
kol would prescrib bayer bellu health asset gefapix even slightli less
effect assum tast effect expect patient take therapi year-
round would attempt lower dose eventu take therapi
kol believ antagonist drug class winner thu far chronic cough
clinic pulmonologist
head one largest
cough center europ
involv
develop er
investig chronic
cough trial variou
physician gener understand mechan treat refractory/idiopath
chronic cough averag patient seen six differ doctor refer
kol cough clinic undergon varieti unnecessari test
kol note merck tri thread needl maxim efficaci minim
tast effect phase trial believ bayer bellu health superior
asset compar gefapix domin market
given lack taste-rel bayer bellu health product allow physician
possibl escal dose without side effect
base enhanc select recent phase result kol believ blu-
potenti less tast effect compar either bayer asset well
kol emphas chronic cough heterogen diseas expect antagonist
effect patient howev biomark help
identifi patient like respond
kol concern mild liver enzym elev bid
sinc transient occur therapeut dose expect safeti
issu later trial given data that present
professor respiratori
medicin head one
largest cough
chronic cough trial
kol note receptor commonli found nodos c-fiber
deep within lung tissu instead respiratori tract therefor like
involv cough compar
howev kol acknowledg receptor alon gener action
potenti strong enough elicit current anim model
ask correl anim model human kol state
guinea pig model help term identifi target mechan target
engag respiratori diseas may provid direct represent efficaci
human seen mani trp modul
kol also expect select antagonist bayer bellu health asset
avoid tast disturb retain anti-tuss efficaci
kol believ avail copd asthma drug effect chronic cough
havent mani studi conduct drug measur cough
reduct endpoint mani kol copd patient standard care still
cough time per hour
note insight taken
base avail data kol believ antagonist lead drug class
chronic cough note patient gener clean airway compar respiratori
condit atp would gener driver cough
howev kol believ receptor may play larg role chronic cough
research interest
neuroplast
involv airway
consult scientif
advisori board member
guinea pig model kol work atp appear stimul jugular c-
fiber major receptor locat kol acknowledg
research unsur translat guinea pig model chronic cough human
intrigu bellu health preclin data
kol also note activ receptor atp result rapid action
potenti caus depolar membran enough reach threshold
activ voltage-g sodium channel activ receptor
hand gener result much larger current
hypothesi correct kol note bellu health might reduc anti-tuss efficaci
product remov tast effect
went back kol spoke assess opinion
possibl oppos view cite differ anim model vs
human bellu health preclin phase data
member neom
institut involv
research develop
licens bellu health
neom institut establish close astrazeneca site montreal not-for-
profit focus develop asset point licens other exchang
percent proce facil equip therapeut program includ
asset gift az
specif design select bind receptor
mind preclin data gener cro affer use asset af-
see bellu ideal partner note lot interest
antagonist bellu move quick licens process mention deal could
probabl done larger compani time process
expert excit pk profil report safeti agre go-forward
dose strategi believ confirm origin hypothesi involv chronic
cough associ tast
expert believ may effect addit indic given role sensori
neuron throughout mani system bodi
tabl content
background inform chronic
potenti best-in-class antagonist chronic
phase clinic data
market opportun chronic
drug develop chronic
potenti indic develop
partner candid pipelin
model
analyst certif disclosur research rate
bellu health clinical-stag biopharmaceut compani base laval quebec develop highli select
receptor antagonist treatment chronic cough share trade toronto stock exchang
ticker blu
novemb bellu health report posit top-lin result phase trial demonstr
asset safe well-toler gener free tast disturb associ lead antagonist
bellu expect initi clinic phase ii trial top-line result come
given receptor mediat atp modul sensori pathway widespread tissu distribut across
bodi potenti expand indic includ endometriosis-rel pain bayer
merck antagonist
decemb bellu health close financ led healthcare-ded investor support develop
chronic cough
bellu health also econom interest partner program
pulmonari sarcoidosi phelan mcdermid
syndrom amo pharma homozyg alzheim
presid chief execut offic
serv ceo sinc januari
previous oversaw licens partner
activ bellu health
past experi invest
oper activ picchio pharma
respons bellu health financ
administr function sinc
previous corpor control
biochem pharma six year
direct drug develop clinic
program bellu health sinc march
previous clinic scientist
product team leader hoechst marion
roussel sanofi-aventi
overse bellu health licens
previous director licens
held bd
posit caprion pharmaceut
upcom catalyst antagonist drug class
addit compani mileston believ catalyst within drug class
specif merck bayer antagonist strong readthrough bellu health
submit ind file
initi phase ii clinic studi
present complet phase data medic confer
present top-lin phase ii data
complet phase i/ii studi chronic cough
complet gefapix phase iia studi endometriosis-rel pain
complet gefapix phase studi chronic cough
complet gefapix longer phase studi chronic cough
chang daytim cough frequenc
baselin end treatment period
gefapix provid proof-of-concept
june up-front
potenti mileston demonstr efficaci multipl chronic cough studi
double-blind placebo-control singl center crossov studi patient
patient receiv mg gefapix placebo daili qd week
refractory/idiopath chronic cough durat
separ washout period
primari endpoint daytim object cough frequenc week treatment
assess ambulatori cough record
reduct cough count intent-to-treat analysi
imput miss data reduct per-protocol analysi
daytim cough frequenc fell coughs/hour treat
patient compar coughs/hour placebo group
howev patient report tast disturb revers hour
discontinu patient discontinu treatment due tast
tast disturb hypothes result receptor
engag gefapix entir select
gefapix remain clinic valid lower dose
due high rate tast disturb previou studi merck/affer
conduct multipl phase ii trial lower dose gefapix attempt
determin dose reduc cough frequenc minim
double-blind placebo-control parallel studi refractori chronic
chang baselin awak cough frequenc
cough patient random receiv placebo mg
mg mg gefapix twice daili bid
primari endpoint chang baselin awak cough frequenc
week treatment document digit record devic
dose show reduct awak cough frequenc mg bid
dose demonstr decreas baselin statist signific
decreas compar placebo
cough frequenc data support improv patient-report
cough sever measur subject visual analog scale millimet
mg bid gefapix demonstr mm decreas
baselin signific mm decreas compar placebo
cough sever
estim percent chang placebo
green present intern symposium cough merck present american thorac societi
still cant pass tast test
efficaci dose mg bid patient still report high degre tast disturb patient report form
tast alter very/extrem bothersom tast effect patient discontinu treatment due taste-rel ae
percent patient report tast
gefapix efficaci data favor statist signific mg bid high frequenc tast disturb
treatment discontinu result taste-rel somewhat problemat given chronic natur diseas
green present intern symposium cough merck present american thorac societi
report case tast disturb gefapix
tast alteration/loss associ gefapix also report particip previou phase ii interstiti cystiti ic
bladder pain syndrom bp trial sponsor shown blog post
disclaim way
ensur post
actual particip trial
on-going phase program gefapix chronic cough
adult patient diagnos refractori idiopath chronic cough year
random treatment group mg gefapix bid mg gefapix bid placebo
note like avoid major tast less effect effect signific tast effect
studi period extens period
studi period extens period
follow
follow
cough frequenc week use digit record percent particip experienc
ae week percent discontinu due week
chang baselin awak cough per hour week use chest contact sensor percent
particip mm improv cough sever use va baselin week
go phase trial merck struggl identifi optim dose gefapix strong cough frequenc reduct
limit tast disturb creat signific opportun given favor toler profil
background inform chronic cough
chronic cough
chronic cough defin cough week
classif cough
cough last week
cough last week
cough last week
chronic cough respond medic treatment
sex distribut chronic cough patient visit
commonli associ pulmonari diseas
asthma copd well upper airway disord
rhinosinus
chronic cough signific impact patient qol
common reason outpati visit us
chest pain headach sore throat psychosoci
complic consist insomnia depress anxieti
social embarrass
chronic cough patient particip
survey across world-wide specialti clinic femal
exactli known preponder
femal believ due hormon
differ cough reflex sensit
demograph profil otherwis homogen
signifi diseas influenc race
geograph factor
pathophysiolog cough reflex arc
normal condit cough import defens mechan
help clear excess secret foreign materi individu airway
start stimul complex reflex arc
cough receptor trigger either mechan chemic stimuli
send impuls via vagu nerv affer pathway cough
center medulla also known nucleu tractu solitariu
subtyp affer nerv categor base differ
myelin conduct veloc origin termin locat includ
rapidli adapt receptor rar respond chang
mechan properti work subtyp induc cough
slowli adapt stretch receptor sar also sensit
mechan forc facilit cough via activ neuron
c-fiber common affer nerv activ
bradykinin agonist ionotrop receptor innerv airway
epithelium effector structur
cough center medulla gener effer signal travel
via vagu phrenic spinal motor nerv inspiratori expiratori
muscl order elicit cough
stimul cough reflex arc
irrit cough receptor
found larynx supralaryng area trachea bronchi
esophagu stomach
cough center medulla organ
product cough
polverino et al multidisciplinari respiratori medicin taylor-clark current opinion pharmacolog
cough reflex import becom excess even
damag patient whose airway becom hypersensit
case initi cough may caus cellular injuri
inflamm trigger continu cycl cough
potenti harm airway mucosa
affer pathway chronic cough patient experi
prolong sensit may return quiescent normal state
cough reflex hypersensit lead increas
respons stimuli chronic cough patient
bodi percept stimuli increas hyperesthesia
activ threshold autonom reflex decreas lead
intens respons hyperreflexia
mechan cough reflex hypersensit current known
hypothes relat plastic variou affer
nerv driven chang ion channel
antagonist fail demonstr
signific benefit reduc cough frequenc improv
cough-specif qol chronic cough patient
cough reflex hypersensit recent character provid better insight underli caus
refractory/idiopath chronic cough valid condit uniqu diseas rather mere symptom
song moric allergi asthma immunolog research ford undem frontier cellular neurosci
play larg role chronic cough
receptor trimer ligand-g ion channel express c-fiber
neuron activ extracellular atp
atp bind subunit trimer caus flex togeth allow
separ membrane-span region open central channel
receptor widespread tissu distribut includ smooth muscl cell
central nervou system primari affer nerv immun cell
primari affer nerv homomer heteromer receptor
import role initi action potenti ionic current kinet
respons atp sensori cell differ
major jugular dorsal root ganglia innerv lung shown
esophagu primarili express mrna littl mrna express
period chronic cough atp releas heighten amount result
cellular damag signal pick receptor lead
hyperexcit primari affer nerv
north philosoph transact royal societi biolog scienc kwong et al lung cellular molecular physiolog
heterotrim link tast function
hand laryng chemoreceptor found tast bud
tast test wt double-ko mice
innerv nerv fiber express
order better character effect receptor tast
double-ko mice evalu two-bottl prefer test
compar wt ko mice favor artifici sweeten
saccharin monosodium glutam sucros monosodium
glutam distast bitter agent quinin denatonium
knockout receptor requir tast loss
two-bottl test singl ko mice loss either
demonstr moder chang tast behavior
suggest tast greatli dictat
heterotrim homomer trimer help
explain tast disturb associ gefapix
receptor cell tast bud releas atp respons stimul
turn activ gustatori nerv send impuls brain
asset much select vs
unlik evad heterotrim complet therefor level
tast disturb like occur antagonist support
phase data
finger et al scienc kinnamon finger frontier cellular neurosci
current treatment chronic cough
current approv therapi treatment chronic cough rather physician tend follow systemat algorithm aim
address common condit coexist chronic cough rather cough sampl algorithm shown next slide
evid treat underli condit larg base uncontrol studi signific placebo respons common
poor success rate reduc cough frequenc sever mani patient suspect etiolog led kol believ
underli condit aggrav rather primari caus chronic cough
chronic cough
includ number etiolog includ allerg nonallerg rhiniti acut nasopharyng sinus
decongest nasal oral antihistamin nasal glucocorticoid nasal ipratropium depend patient symptom
inhal glucocorticoid budesonid fluticason beclomethason decreas inflamm airway
inhal bronchodil albuterol open airway
lifestyl chang includ smoke cessat healthi diet weight loss
proton pump inhibitor ppi omeprazol esomeprazol lansoprazol slow product stomach acid
inhal glucocorticoid budesonid fluticason beclomethason decreas inflamm airway
use angiotensin convert
discontinu ace inhibitor caus chronic cough patient receiv therapi
jiang et al european respiratori journal pavord chung lancet accp er bt cicada clinic guidelin
evalu treatment guidelin similar
recommend develop
american colleg chest physician accp
treatment refractory/idiopath chronic cough
therapeut choic refractory/idiopath chronic cough limit
evalu refractory/idiopath chronic cough
term therapi efficaci safe
agent improv patient qol associ
signific kol especi us hesit use morphin due
opiat epidem would heavili prescrib non-addict therapi
gabapentin significantli improv cough frequenc sever patient
qol includ fatigu nausea blur vision memori loss
associ agent show signific
improv cough sever associ
non-pharmacolog therapi speech languag intervent
vocal hygien techniqu strategi reduc vocal cord dysfunct
effect reduc cough sever rare use
combin speech therapi pregabalin shown
effect speech therapi alon singl rct
limit term efficaci durat relief
chronic cough remain area unmet need
european lung foundat creat on-line survey assess
impact chronic cough patient qol gaug patient durat
across countri januari april
cough durat survey respond
median durat cough year
patient cough durat year
patient seen doctor least cough
patient visit physician time
respond report cough affect qol
felt fed depress result cough
respond felt doctor dealt cough
particip report limit benefit
medic tri chronic cough
given lack novel approv therapi last year refractory/idiopath chronic cough remain signific challeng
physician world-wide safe non-narcot anti-tuss therapi greatli need challeng patient popul
potenti best-in-class antagonist chronic cough
histori overview
potent highli select oral bioavail second-gener purinoceptor
antagonist current develop treatment chronic cough
asset first develop astrazeneca nyse azn manag pain indic like
osteoarthr bladder pain syndrom inhibit atp activ receptor
similar program advanc roch licens product merck gsk
az shut montreal facil gift program neom institut licens
asset bellu health cash equiti low doubl digit percent revenu
share agreement case licensing/acquisit low singl digit royalti sale
bellu health expect initi phase ii trial top-lin result
osteoarthr
astrazeneca
astrazeneca close
licens neom
cash incent
phase studi
declar clinic
drug candid chronic cough
chronic cough
bellu compani present neom innov approach earli drug develop
highli select receptor
preclin toxicolog studi rat dog return clean safeti
profil drug-lik characterist
emesi vomit one preclin ae observ dog
present high dose mg/kg/day go forward dose
expect bid
ae note preclin studi gefapix
potent select human
comparison gefapix
half maxim inhibitori concentr measur
flipr calcium assay kit clone human channel
express cell
gefapix display inhibitori impact non-
subunit contain receptor human
channel atp-competit
bayer db bayn shionogi develop
antagonist detail competit landscap section chronic
cough select ratio respect
metabol stabil human hepatocyt
cross blood-brain barrier
note gener behavior neurolog function
treat rat
high safeti margin rat dog toxic studi
given much higher select vs expect mitig cough frequenc anim model
clinic studi shown gefapix without mani accompani advers tast disturb
preclin result inhibit drg neuron sensit
dorsal root ganglion neuron rat revers hypersensit prompt atp shown
patch clamp record result support hypothesi main driver chronic cough
control gefapix
administ oral mg/kg seven
group six guinea pig
anim expos citric acid
aerosol histamin mm aerosol
tussiv agent two hour treatment cough
count measur next minut
cough frequenc compar control
statist signific reduct
cough mg/kg compar control
mg/kg compar control
gefapix statist signific cough
reduct mg/kg compar control
research unsur repres guinea pig respiratori model chronic cough human
shown exhibit anti-tuss efficaci dose-depend compar gefapix
preclin result durat effect studi
mg/kg singl dose control
gefapix administ oral
seven group six guinea pig
anim expos citric acid
aerosol histamin mm aerosol
variou time treatment cough count
measur next minut
cough frequenc reduct statist
signific hour
hour gefapix
therapi demonstr anti-tuss
effect hour post-treat administr
support bellu health approach twice
also shown compar durat effect compar gefapix guinea pig cough model
control gefapix
administ intraperiton mg/kg
two group rat
anim water fast overnight
present bottl water bottl
quinin bitter plasma
concentr treatment peak
volum bottl measur
minut consumpt
rat treat gefapix drank approxim
time quinin control
dose statist signific rat treat
drank amount compar
control group
rat tast test associ meaning tast loss plagu gefapix given asset select
preclin efficaci data believ potenti best-in-class antagonist
phase clinic data
design phase trial
random double-blind placebo-control phase studi oral administ assess
safeti toler tast percept pharmacokinet profil healthi adult subject
particip random cohort
subject placebo
evalu singl dose mg
mg administ oral
food interact test mg
particip random cohort
subject placebo
evalu multipl dose
mg administ twice daili
primari endpoint number sever treatment emerg advers event teae dose follow hour
last dose
secondari endpoint maximum plasma concentr cmax normal fed condit hour last dose
area curv auc normal fed condit hour last dose
plasma half-lif hour support
rapidli absorb tmax hour
dose proport linear
interact food
repeat administr multipl
optim therapeut dose
project twice-daili base
reach level system exposur
equival show maxim target
inhibit receptor
concentr bid
gefapix shown clinic signific
phase iib studi correct
differ receptor potenc
molecul
note full pharmacodynam profil provid
top-lin readout phase data
extrapol efficaci seen preclin
studi well phase safeti data
found safe well toler healthi subject especi project optim therapeut dose mg
overal incid compar placebo group vs
sae report dose level none particip discontinu treatment due ae
report mild accord princip investig
signific mean chang identifi vital sign electrocardiogram ecg clinic laboratori valu
one patient experienc gener numb bodi pain along mild liver enzym elev day treatment mg bid
supratherapeut patient normal follow-up kol spoke concern occurr
incid subject singl multipl ascend dose cohort
number subject present ae
especi come tast
limit tast disturb report project optim therapeut dose
one patient receiv bid report episod transient tast alter first day treatment experi
tast disturb remain day
incid tast alter dose-depend like coincid degre inhibit receptor
view posit confirm target engag human
subject receiv supra-therapeut dose report mild transient partial loss tast similar tast event
dose disturb experienc first dose throughout remaind studi
none subject experienc complet tast loss dose
tast disturb consid transient sporad one incid categor mild except moder tast ae
incid tast singl multipl ascend dose cohort
number subject present ae
indirect comparison gefapix
seen gefapix phase studi meaning differ tast effect profil healthi volunt
refractory/idiopath chronic cough patient treat asset allow us make indirect comparison two drug
recommend dose much lower incid tast alter partial complet tast loss compar gefapix
patient treat gefapix experienc tast disturb compar
tast disturb expect antagonist matter select
mg singl
mg singl
mg bid week
superior tast profil dose compar gefapix given select assum compar efficaci
chronic cough patient potenti best-in-class asset larg market
effect gefapix cough reflex sensit chronic cough particip clinicaltri gov merck present american thorac societi
develop chronic cough
bellu plan initi random double-blind placebo-control phase ii dose-escal crossov studi shown
better assess safeti efficaci confirm optim dose regimen top-lin result expect
unexplain refractori chronic cough patient year diagnosi enrol across clinic site locat us uk
dose level test bid escal interv
patient receiv dose make studi design robust
primari endpoint studi reduct awak cough frequenc measur digit cough record similar
endpoint use phase iib studi gefapix
septemb bellu health appoint intern clinic advisori board compris clinic leader manag
chronic cough provid strateg guidanc develop program
major kol talk consid one main driver refractory/idiopath chronic cough believ
compar gefapix term efficaci phase ii trial without presenc tast disturb
given lead tast loss kol also note slightli less effect gefapix still favor
market opportun chronic cough
epidemiolog chronic cough
due vari definit chronic cough past preval diseas report across wide spectrum
shown consid public literatur come consensu diseas affect
popul kol believ actual preval may lower assum estim
adult
adult b/w age
adult b/w age
adult b/w age
adult b/w age
adult
children b/w age
adult
adult
chronic cough link smoke obes mental health
chronic cough defin cough bout last week
chronic cough defin cough mo success year
differ preval base gender
nocturn cough common
studi analyz chronic cough primari outcom
increas preval chronic cough airflow obstruct
chronic cough defin product cough last mo /year
preval age group age group
common caus smoke uac copd asthma
durat treatment kol agre vast major
chronic cough patient take chronic
basi howev may requir therapi coupl
month cold upper airway infect
patient chronic cough
patient refractori suggest
address patient popul opportun multipli futur
addit studi run payer agre includ refractory/idiopath
patient diagnos week year
kol unsur whether trial inclus criteria year diagnosi includ label payer
us expect implement prior author pa restrict order limit address patient popul
prescript pattern novel chronic cough therapi
torreya partner hire bellu health perform
assess market potenti chronic cough
conduct interview commun pcp specialist kol
pcp handl largest volum patient less like
incorpor novel therapi treatment paradigm unless product
recommend specialist treatment guidelin
pcp earliest point contact patient gener
pulmonologist allergist immunologist aggress
treatment chronic cough expect earli adopt
howev expect enter clinic year later
gefapix assum posit clinic efficaci merck asset expect
adopt much quicker given decreas tast
disturb overal familiar drug class
prescript level may highli depend payer manag
cough specialist like involv prior
author step edit mechan place ensur use
refractory/idiopath chronic cough patient diagnosi
price base compar analog
market analysi torreya partner also identifi therapi shown target similarly-s patient popul compar
market dynam brand gener and/or over-the-counter therapi avail payer discuss analysi analog bellu health
believ could price per month price like influenc cost gefapix well
note revenu build incorpor monthli net price time launch
partial-onset seizur
patient year
older
constip
pediatr base bodi
inhal
bid
risk-adjust sale project
diseas preval estim adult popul chronic cough defin week
estim assum adult condit sinc seem high base real-world observ experi
patient condit roughli estim chronic cough year popul bellu plan enrol
upcom phase ii trial incorpor estim adult patient us time launch could
elig antagonist note could also get use patient chronic cough year would
substanti increas market opportun drug-class
diseas growth rate assum diseas growth rate line us popul
market entri model assum market entri late us rest world assumpt behind
top-line data phase trial chronic cough year timelin data base roughli long take
merck run phase trial gefapix
end file nda
potenti approv launch
price discuss prior seem reason look treatment compar market
model use net price start although expect price compet antagonist greatli influenc
price assum price increas line us inflat rate
risk-adjust sale project
penetr rate given assumpt third market behind merck bayer best-in-class estim
could captur market drug class use chronic cough patient diagnos year base
studi data show patient seen doctor least time condit expect mani physician tri
treatment path first use system medic estim achiev peak penetr patient
chronic cough year expect reach year market
complianc note kol agre vast major chronic cough patient take chronic basi
howev may requir therapi coupl month cold upper airway infect assign complianc rate
account potenti miss dose given treatment bid percentag also consist chronic treatment
current approv side note kol spoke note heterogen chronic cough antagonist
expect effect patient depend final product profil compet program
probabl success given posit data gefapix mechanist rational target chronic cough phase
data preclin result good reason believ success develop
potenti best-in-class compound current assign probabl success stage develop although
number like shift base futur clinic data program bayer merck
net sale assumpt lead risk-adjust sale non-risk adjust sale
howev estim like shift data releas compet program mention also potenti
antagonist use patient chronic cough year would increas market opportun
risk-adjust sale project
preval chronic cough
patient diagnos year
patient treat
patient respond
estim net annual
chang price
probabl adjust row sale us sale
us row probabl adjust sale usd
us row probabl adjust sale cad
drug develop chronic cough
multipl drug class develop chronic cough antagonist advanc demonstr
benefit clinic kol believ antagonist work patient given heterogen natur diseas
octob evotec xtra evt bayer enter multi-target collabor develop candid endometriosi base
success affer asset allianc expand includ chronic cough two product enter clinic indic
current three on-going trial
phase i/ii studi evalu ascend oral dose healthi volunt chronic cough patient
phase studi determin extent drug-drug interact itraconazol
phase i/ii studi evalu ascend oral dose healthi volunt chronic cough patient
arm studi also investig effect asset pharmacokinet sub-therapeut dose midazolam
bayer disclos inform either asset howev june evotec announc mileston payment
result asset enter phase ii clinic studi chronic cough later confirm initi data
program could come earli base primari complet studi estim mid-year
bayer reveal characterist
asset patent claim
select compar
gefapix select blu-
least one asset phase ii studi
clinicaltri gov bayer interim report third quarter evotec press releas
bayer conduct drug-drug interact
ddi studi parallel phase i/ii
clinic studi may signifi
safeti issu target relat
increas specif enough
overcom tast disturb associ
gefapix
addit benefit tast disturb
ddi studi result influenc
dose patient select use
antagonist develop
shionogi develop pyrrolinon deriv
receptor antagonist analges agent neuropath pain
antituss agent refractory/idiopath chronic cough
asset develop in-hous phase
phase ii clinic trial japan pain cough respect
phase ii poc cough studi initi end
phase data made public
global studi asset initi
base preclin studi asset
select note optim
antagonist shionogi develop may
vs
asset exhibit greater select merck
bayer asset still select
ossianix expand partnership lundbeck cpse lun
continu develop variabl new antigen receptor
vnar antagonist target
develop neuropath pain compani
note expect fewer off-target effect lower dose
frequenc compar gefapix
develop statu asset known
decemb integr molecular announc
success gener potent antibodi neuropath pain
use mp discoveri engin
character antibodi reveal bind epitop
high specif sub-nanomolar affin
inform made public program
knowledg still best select antagonist develop ossianix integr molecular
could possibl pursu chronic cough futur base clinic valid
tobinaga et al bioorgan medicin chemistri letter shionogi ossianix integr molecular press releas
rational target receptor
substanc sp natur occur tachykinin
neuropeptid wide distribut peripher nerv
agonist ligand receptor
evid show substanc
involv cough reflex hypersensit
guinea pig model introduct airway sp
caus bronchospasm edema vasodil
evok heighten activ rar
conflict report plasma level
sp human seem elev patient
subacut chronic cough
merck emend aprepit approv chemo-induc
nausea vomit first antagonist
show anti-tuss effect lung
improv awak cough frequenc sever
vs placebo lung cancer patient cough
howev aprepit develop
on-going trial chronic cough
antagonist develop
nerr obtain right orvepit select
antagonist receptor divest gsk
asset initi develop antidepress
show enough benefit justifi develop
open-label phase iia studi result
meaning improv object cough frequenc
week treatment patient demonstr
statist signific reduct coughs/hr
decreas baselin
follow-up daytim cough frequenc
reduct sustain decreas baselin
signifi normal effect cough reflex
placebo-control poc phase iib studi
serlopit select small molecul inhibitor
origin licens merck current
develop psoriasi prurigo nodulari
asset dose patient shown
safe well-toler year treatment
ii studi refractori chronic cough
week treatment placebo group
demonstr greater reduct awak cough
frequenc baselin compar serlopit group
placebo-tr patient experienc
greater reduct baselin cough frequenc
week compar serlopitant-tr patient
serlopit also fail meet either endpoint phase ii studi
on-going assess safeti efficaci qd
orvepit cough patient data expect
although interest target yet clinic valid placebo-control random studi
atop dermat april
refractory/idiopath chronic cough recent failur serlopit serv warn asset class
clinicaltri gov smith et al american journal respiratori critic medicin file press releas
phylogen mammalian trp channel
rational target trp channel
transient receptor potenti trp channel integr membrane-bound
protein function ion channel
channel express across multipl tissu organ system
serv highli specif sensor rang physic chemic stimuli
trp channel split seven subfamili differ term
gate mechan sequenc divers allow develop
truli select modul
activ trp channel lead depolar cellular
membran prompt voltage-depend channel transfer import
signal ion across variou function
trp channel commonli found respiratori tract neuron
non-neuron cell previous associ mani
respiratori diseas like asthma copd
specif vanilloid ankyrin melastatin
channel express c-fiber activ airway
similar believ ion channel may play role
cough reflex hypersensit clinic data support
hypothesi thu far
trp modul develop
antagonist associ
temperatur disturb associ drug class
seriou note toxicolog studi suggest
asset suitabl multipl oral dose human
adren vacuol
patient treat demonstr benefit
cough frequenc sever qol compar placebo
antagonist current
develop neuropath pain phase ii studi
end asset assess placebo-
control phase iia studi patient refractori chronic
cough clinic data trial publish
longer develop indic
potent select channel blocker
evalu random double-blind
placebo-control phase ii two-period crossov studi
januari studi termin due lack
efficaci target popul gsk recent announc
halt develop asset altogeth
anoth select potent inhibitor
complet phase trial pain diabet neuropathi allerg
asthma activ clinic trial on-going
much known asset whether
develop chronic cough sinc compani websit
current construct
base divers seri failur trp modul drug class seem like target singl one
receptor peripher nervou system enough mitig refractory/idiopath chronic cough
clinicaltri gov khalid et al journal allergi clinic immunolog compani press releas
effect nicotine-contain e-cig exposur
cough reflex sensit
nachr modul chronic cough
neuron nicotin acetylcholin receptor nachr belong famili ligand-
gate ion channel modul neurotransmiss throughout brain
includ receptor gabaa glycin serotonin
previou studi shown nicotin exposur healthi nonsmok significantli
reduc cough reflex sensit determin capsaicin cough challeng
subject cough immedi inhal e-cig
nicotin due stimul nachr experienc much less cough
minut compar inhal non-nicotin e-cig
specif activ common subtyp nachr believ
account major anti-tuss effect associ nicotin
preclin studi guinea pig administr agonist inhibit
cough respons similar degre nicotin
attenua privat bradaniclin novel small molecul agonist acquir
catalyst bioscienc cover cbio activ
subtyp gabaerg interneuron brainstem order mitig cough
random dose-escal crossov phase ii studi
assess safeti influenc cough frequenc bradaniclin
refractori chronic cough patient data expect ye
dr michael kitt affer previou join attenua ceo april
corradi bouzat molecular pharmacolog dicpiniga et al chest canning liu american journal respiratori critic medicin
antagon chronic cough
stimul ion-gat channel like necessari
elicit cough voltage-g sodium channel nav actual respons
action potenti initi propag primari affer nerv
differ action potenti current frequenc
wt guinea pig neuron
nav compris nine channel refer notabl
shown innerv respiratori tract channel
upregul presenc inflamm inflammatori
mediat may lead cough reflex hypersensit
shown guinea pig model right vagal sensori neuron much less
excit absenc requir might larger stimulu elicit
action potenti less like fire high frequenc
mani compani tri develop antagonist none success
demonstr clinic benefit placebo-control trial
well toler demonstr meaning anti-tuss
effect placebo-control studi chronic idiopath cough patient
privat spun harvard neurobiolog lab also
develop antagonist littl known program compani
nachr modul antagon limit mechanist proof concept antagonist alreadi fail
clinic wait attenua data determin whether nicotin agonist may serv anoth viabl therapi option
muroi undem lung aparici et al european respiratori journal smith et al journal clinic pharmacolog therapi
potenti indic develop
receptor involv multipl pain disord
mention receptor mediat atp modul sensori
across multitud organ system
pathway widespread tissu distribut across bodi
atp releas central termin activ affer greater
amount condit injuri inflamm stress
lead sensit primari affer nerv
notabl dysregul sensit sensori neuron link
multipl version pain well irrit condit like overact
bladder irrit bowel syndrom chronic itch
inflammatori joint musculoskelet pain atp elev
inflam damag tissu joint commonli found
synovi fluid arthrit patient note gefapix fail prior
studi osteoarthr
viscer pain sensori fiber viscer organ especi bladder
express high level period chronic inflamm
injuri nerv hypersensit distort percept bladder
fill distens pain
neuropath pain model post-herpet neuralgia phn diabet
peripher neuropathi dpn trigemin neuralgia tgn
radiculopathi demonstr increas sensit atp
mechan neuron sensit yet fulli understood
potenti endometriosis-rel pain
endometriosi character presenc endometri gland stroma-lik lesion
outsid uteru patient gener present symptom intermenstru bleed
dysmenorrhea dyspareunia dyschezia dysuria
diseas affect women reproduct age women
chronic pelvic pain
previou studi demonstr level elev endometriosi lesion
correl pain unknown whether channel associ well
howev recent studi analyz tissu sampl women laparoscop surgeri
endometriosi discov play role endometriosis-rel pain
level express ectop ec eutop eu endometrium
endometriosi patient significantli higher control con endometrium
tissu women without endometriosi top figur
addit express significantli higher endometriosi patient pain
without pain ectop eutop endometrium bottom figur
base compel preclin data rat model endometriosis-rel pain becom
popular target antagonist merck gefapix recent enter phase ii clinic
studi one bayer asset phase develop
potenti expand pain indic endometriosi model
incorpor could provid addit upsid estim
past present clinic program gefapix
moder sever
acut cough upper
persist cough
subject asthma
osteoarthr knee
primari efficaci endpoint chang baselin averag daili pelvic pain score
estim complet octob
clinic studi discontinu februari interim efficaci gefapix mg
bayer also develop indic
bid support continu clinic develop indic
potenti issu trial design patient acut cough recov spontan
primari efficaci endpoint awak object cough frequenc chang baselin
awak cough frequenc week treatment bid
data publish trial indic current pursu phase
primari efficaci endpoint respons two dose level gefapix
compar placebo provoc methacholin
data publish trial indic current pursu phase ii
patient treat gefapix bid week demonstr posit non-
signific improv npr urinari urgenc patient-report endpoint
similar studi frequent report ae dysgeusia/hypogeusia
reduct weekli npr patient-report pain scale primari endpoint
numer statist better gefapixant-tr arm compar placebo
patient report tast alter loss discontinu treatment result
partner candid pipelin
project complet fund partner model time account program provid addit upsid potenti
ind clear
bellu enter sale/licens agreement
ww right kiacta exchang
up-front fee revenu share
kiacta previous fail meet primari
endpoint phase studi aa amyloidosi
bellu enter development/licens
agreement ww right
exchang royalti sale revenu share
asset acquir thallion august
bellu health enter licens
agreement ww right
exchang royalti sale revenu share
high risk asset low probabl success
bellu health exclus world-wide licens neom institut develop commerci includ broad
comprehens patent portfolio asset relat compound
patent protect cover composit matter imidazopyridin compound secur major
pharmaceut market includ japan juli europ april us china
patent expir date includ potenti patent term extens
patent applic similar claim pend industri nation
bellu recent announc us patent trademark offic issu patent octob claim use
imidazopyridin compound select receptor minim tast disturb patient treat chronic cough
patent expir exclud patent term extens prolong ip protect us addit year
bellu health compani present quarterli report
model valuat
dcf sensit analysi
profit loss
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect secur subject
compani research analyst cover research view express report accur reflect person view
subject secur subject compani part research analyst compens directli
indirectli relat specif recommend view express research analyst report
